Pomerantz Appointed Lead Counsel in Silverback Therapeutics Securities Litigation

On February 23, 2022, U.S. Magistrate Judge Theresa L. Fricke of the Western District of Washington (Tacoma) appointed Pomerantz LLP as Lead Counsel on behalf of Lead Plaintiff, Benjamin Dresner, and the class, in Dresner v. Silverback Therapeutics, Inc., 21-cv-1499 (W.D. Wash.). Silverback Therapeutics, Inc. (“Silverback” or the “Company”) is a biopharmaceutical company that develops tissue-targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. The litigation concerns allegations that Silverback’s Offering Documents for its December 2020 IPO misrepresented the efficacy and commercial…